Predicting the effect of statins on cancer risk using genetic variants from a Mendelian randomization study in the UK Biobank

Keyphrases

• Genetic Variants 100%
• Statins 100%
• Mendelian Randomization 100%
• UK Biobank 100%
• Cancer Risk 100%
• Confidence Interval 33%
• Low-density Lipoprotein Cholesterol (LDL-C) 33%
• Odds Ratio 33%
• Statin Therapy 33%
• Lipid-lowering Treatment 33%
• Gene-rich Regions 33%
• Non-associated 16%
• Independent Pathway 16%
• Low-density Lipoprotein Receptor 16%
• Using Evidence 16%
• Lipids 16%
• Cholesterol 16%
• Targeted Treatment 16%
• Oncogenic Role 16%
• Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) 16%
• Site-specific Cancer 16%
• Lipid Effects 16%
• APOC3 16%
• Alternative Lipids 16%
• Human Genetics 16%
• HMGCR Gene 16%
• Anticarcinogenic Effects 16%
• Niemann-Pick C1-like 1 (NPC1L1) 16%

Medicine and Dentistry

• Statin 100%
• Mendelian Randomization Analysis 100%
• Cancer Risk 100%
• UK Biobank 100%
• Malignant Neoplasm 33%
• Low Density Lipoprotein Cholesterol 33%
• Odds Ratio 33%
• Human Genetics 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 100%
• Malignant Neoplasm 50%
• Statin (Protein) 50%
• Low Density Lipoprotein Cholesterol 50%
• NPC1L1 25%